TY  - JOUR
A1  - Adam, Elisabeth
A1  - Schmid, Benedikt
A1  - Sonntagbauer, Michael
A1  - Kranke, Peter
A1  - Zacharowski, Kai
A1  - Meybohm, Patrick
T1  - Fibrin-derived peptide Bβ15-42 (FX06) as salvage treatment in critically ill patients with COVID-19-associated acute respiratory distress syndrome
T2  - Critical care
KW  - Critical care
KW  - Respiratory distress syndrome
KW  - adult
KW  - COVID-19
KW  - Therapies
KW  - investigational
KW  - Pulmonary edema
KW  - Immunomodulatory agents
Y1  - 2020
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/75719
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-757196
SN  - 1466-609X
N1  - The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
N1  - This study was funded by institutional funds of both University hospitals. FX06 was provided by the manufacturer (F4 Pharma, Vienna, Austria). No further external funding, especially none through the pharmaceutical manufacturer, was provided. The Universities of Frankfurt and Wuerzburg are in part owners of the patent of FX06. Open Access funding enabled and
organized by Projekt DEAL.
VL  - 24
IS  - art. 574
SP  - 1
EP  - 4
PB  - BioMed Central ; Springer
CY  - London ; Berlin ; Heidelberg
ER  -